The estimated Net Worth of James R. Empfield is at least $3.44 Milion dollars as of 12 August 2022. James Empfield owns over 65,000 units of Xenon Pharmaceuticals Inc stock worth over $2,898,750 and over the last 9 years he sold XENE stock worth over $0. In addition, he makes $545,000 as Senior Vice President - Drug Discovery at Xenon Pharmaceuticals Inc.
James has made over 3 trades of the Xenon Pharmaceuticals Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 65,000 units of XENE stock worth $275,600 on 12 August 2022.
The largest trade he's ever made was exercising 67,500 units of Xenon Pharmaceuticals Inc stock on 4 March 2022 worth over $501,525. On average, James trades about 10,179 units every 130 days since 2016. As of 12 August 2022 he still owns at least 75,000 units of Xenon Pharmaceuticals Inc stock.
You can see the complete history of James Empfield stock trades at the bottom of the page.
Dr. James R. Empfield Ph.D. serves as Senior Vice President - Drug Discovery of the Company. He is employed by our wholly owned subsidiary, Xenon Pharmaceuticals USA Inc. and has served as our Senior Vice President, Drug Discovery since February 2016. Prior to joining us, Dr. Empfield served as Vice President, Drug Discovery and Chemistry; Co-Site Head of Research, Boston at Vertex Pharmaceuticals Inc. from 2011 until August 2015, where he was jointly responsible for the entire Boston research organization and for delivery of lead optimization projects into preclinical development. From 2006 to 2011, Dr. Empfield was Director, CNS Chemistry Department at Astrazeneca Pharmaceuticals LP and held various other positions at Astrazeneca Pharmaceuticals from 1990 to 2006. Dr. Empfield has a Ph.D. in Chemistry from the University of Pennsylvania, a M.S. in Chemistry from Bucknell University and a B.Sc. in Chemistry from Lebanon Valley College.
As the Senior Vice President - Drug Discovery of Xenon Pharmaceuticals Inc, the total compensation of James Empfield at Xenon Pharmaceuticals Inc is $545,000. There are 6 executives at Xenon Pharmaceuticals Inc getting paid more, with Simon Pimstone having the highest compensation of $2,612,720.
James Empfield is 59, he's been the Senior Vice President - Drug Discovery of Xenon Pharmaceuticals Inc since 2016. There are 9 older and 12 younger executives at Xenon Pharmaceuticals Inc. The oldest executive at Xenon Pharmaceuticals Inc is Michael Tarnow, 74, who is the Independent Chairman of the Board.
James's mailing address filed with the SEC is 200 - 3650 GILMORE WAY, , BURNABY, A1, V5G 4W8.
Over the last 10 years, insiders at Xenon Pharmaceuticals Inc have traded over $12,977,011 worth of Xenon Pharmaceuticals Inc stock and bought 724,015 units worth $2,649,316 . The most active insiders traders include Patrick Machado, Partners L P/Ilbiotechnolog... a Justin D. Gover. On average, Xenon Pharmaceuticals Inc executives and independent directors trade stock every 31 days with the average trade being worth of $818,878. The most recent stock trade was executed by Elizabeth A. Garofalo on 8 March 2024, trading 3,500 units of XENE stock currently worth $64,960.
xenon® (nasdaq: xene) is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as extreme genetics. our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits, or phenotypes. we apply our expertise to predict which phenotypes are caused by single-gene defects. by identifying and characterizing the single-gene defects responsible for such severe phenotypes, we gain valuable insights into their function in human biology and their potential as drug targets. given that these targets are often involved in diseases beyond the rare genetic disorders in which they are first identified, we are developing proprietary product candidates to treat both orphan as well as more prevalent diseases.
Xenon Pharmaceuticals Inc executives and other stock owners filed with the SEC include: